Trial
NCT00923117
Sunitinib to Treat Recurrent Brain Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Glioblastoma Multiforme
Intervention
Sutent (sunitinib)
Why stopped
The study was terminated based on results of an interim analysis for futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-30